Recursion Pharmaceuticals (RXRX) EBIAT (2020 - 2025)
Recursion Pharmaceuticals (RXRX) has disclosed EBIAT for 6 consecutive years, with -$108.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 39.56% year-over-year to -$108.1 million, compared with a TTM value of -$644.8 million through Dec 2025, down 39.06%, and an annual FY2025 reading of -$644.8 million, down 39.06% over the prior year.
- EBIAT was -$108.1 million for Q4 2025 at Recursion Pharmaceuticals, up from -$162.3 million in the prior quarter.
- Across five years, EBIAT topped out at -$30.7 million in Q1 2021 and bottomed at -$202.5 million in Q1 2025.
- Average EBIAT over 5 years is -$93.1 million, with a median of -$84.0 million recorded in 2023.
- The sharpest move saw EBIAT crashed 152.01% in 2021, then soared 39.56% in 2025.
- Year by year, EBIAT stood at -$64.9 million in 2021, then rose by 11.46% to -$57.5 million in 2022, then tumbled by 61.75% to -$93.0 million in 2023, then tumbled by 92.38% to -$178.9 million in 2024, then soared by 39.56% to -$108.1 million in 2025.
- Business Quant data shows EBIAT for RXRX at -$108.1 million in Q4 2025, -$162.3 million in Q3 2025, and -$171.9 million in Q2 2025.